Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence
- PMID: 24007390
- DOI: 10.1111/hiv.12075
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence
Abstract
Objectives: Three-drug nonoccupational post-exposure prophylaxis (NPEP) typically includes co-formulated emtricitabine-tenofovir (FTC-TDF) and a protease inhibitor. However, protease inhibitors can cause significant toxicities, can interact with prescribed and illicit drugs, and work late in the viral cycle. Agents that act before viral integration into host DNA may have efficacy advantages. Raltegravir (RAL) is a good candidate for NPEP as it has few side effects or drug interactions and acts prior to HIV integration. The objective of this study was to investigate the use of RAL in 3-drug NPEP in terms of safety, adherence and tolerability.
Methods: We evaluated 28 days of RAL-FTC-TDF treatment in 86 men and FTC-TDF treatment in 34 men eligible for three- and two-drug NPEP, respectively. We assessed adherence (compared between groups and with nonstudy controls) and clinical and adverse events at weeks 1, 2 and 4, and efficacy at week 12. Analyses were by intention to treat, excluding from the adherence analysis subjects who ceased NPEP because their source was HIV-uninfected.
Results: No participant became infected with HIV. For RAL-FTC-TDF and FTC-TDF, regimen completion rates were 92% and 91% and medication adherence rates were 89% and 90%, respectively. Eight (9%) RAL recipients developed mild myalgias, with four developing transient grade 4 elevations in creatine kinase (two developed both), all of which improved to grade 2 or less by week 4 without RAL discontinuation. Eight prescribed and 37 potential illicit drug interactions with a protease inhibitor were avoided by use of RAL.
Conclusions: RAL-FTC-TDF is well tolerated as NPEP, results in high levels of adherence and avoids potential drug-drug interactions. Patients and clinicians should be aware of the potential for acute muscle toxicity when RAL is used as NPEP.
Keywords: HIV; post-exposure prophylaxis; raltegravir.
© 2013 British HIV Association.
Similar articles
-
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255. HIV Clin Trials. 2011. PMID: 22180523 Clinical Trial.
-
Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.HIV Clin Trials. 2014 Mar-Apr;15(2):51-6. doi: 10.1310/hct1502-51. HIV Clin Trials. 2014. PMID: 24710918 Clinical Trial.
-
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259. AIDS Patient Care STDS. 2010. PMID: 20156091 Clinical Trial.
-
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.Cochrane Database Syst Rev. 2010 Oct 6;(10):CD008740. doi: 10.1002/14651858.CD008740. Cochrane Database Syst Rev. 2010. PMID: 20927777 Review.
-
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. AIDS Patient Care STDS. 2011. PMID: 21284497 Review.
Cited by
-
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.BMC Infect Dis. 2023 Sep 4;23(1):578. doi: 10.1186/s12879-023-08544-x. BMC Infect Dis. 2023. PMID: 37667182 Free PMC article.
-
The Use of HIV Pre- and Postexposure Prophylaxis Among a Web-Based Sample of HIV-Negative and Unknown Status Cisgender and Transgender Sexual Minority Men: Cross-sectional Study.JMIR Public Health Surveill. 2022 Dec 16;8(12):e31237. doi: 10.2196/31237. JMIR Public Health Surveill. 2022. PMID: 36306518 Free PMC article.
-
Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States.AIDS Behav. 2021 Sep;25(9):2929-2940. doi: 10.1007/s10461-021-03189-w. Epub 2021 Feb 19. AIDS Behav. 2021. PMID: 33606134 Free PMC article.
-
Tailored HIV Pre-exposure Prophylaxis (PrEP) Intervention Needs from a Latent Class Analysis Among U.S. Healthcare Providers.AIDS Behav. 2021 Jun;25(6):1751-1760. doi: 10.1007/s10461-020-03105-8. Epub 2020 Nov 20. AIDS Behav. 2021. PMID: 33216244 Free PMC article.
-
HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers.AIDS Behav. 2020 Nov;24(11):3124-3131. doi: 10.1007/s10461-020-02866-6. AIDS Behav. 2020. PMID: 32300991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical